# Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas

> **NCT03136055** · PHASE2 · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 36 (actual)

## Conditions studied

- High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Irinotecan
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT03136055
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-20
- **Primary completion:** 2021-10-31
- **Final completion:** 2021-10-31
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2022-12-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03136055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03136055, "Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03136055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*